Breast Cancer New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Follicular Lymphoma New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma Ulas D. Bayraktar, MD 2022-09-20
Renal Cell Carcinoma New Reference: Nivolumab and Cabozantinib for Advanced RCC Ulas D. Bayraktar, MD 2022-09-20
Nervous System Tumor Thyroid Cancer New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer Ulas D. Bayraktar, MD 2022-09-20
Gastrointestinal Stromal Tumor New Drug: Ripretinib for Advanced GIST Ulas D. Bayraktar, MD 2022-09-20
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Nivolumab for NSCLC Ulas D. Bayraktar, MD 2022-09-20
Mantle cell lymphoma New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2022-09-20
GastroEsophageal Cancer New Protocol: Perioperative FLOT with Trastuzumab and Pertuzumab for her2-Positive Gastroesophageal Cancer Ulas D. Bayraktar, MD 2022-07-16
Acute myeloid leukemia New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML Ulas D. Bayraktar, MD 2022-07-16
